Incidence of respiratory tract sarcoidosis in southern and northern regions of Ukraine

(1)

ɋɈɐȱȺɅɖɇȺ ɆȿȾɂɐɂɇȺ

159

14/

Ɍɨɦ

XI

ɏ

/ 2

ɍȾɄ 616.24-002.18-036.22(477)

Ƚ.Ʌ.Ƚɭɦɟɧɸɤ

Ɂ

Ⱥ

ɏ

ȼ

Ɉ

Ɋ

ɘ

ȼ

Ⱥ

ɇ

ȱ

ɋ

Ɍ

ɖ

ɇ

Ⱥ

ɋ

Ⱥ

Ɋ

Ʉ

Ɉ

Ȳ

Ⱦ

Ɉ

Ɂ

Ɉ

Ɋ

Ƚ

Ⱥ

ɇ

ȱ

ȼ

Ⱦ

ɂ

ɏ

Ⱥ

ɇ

ə

ȼ

ɉ

ȱ

ȼ

Ⱦ

ȿ

ɇ

Ɉ

Ɇ

ɍ

Ɍ

Ⱥ

ɉ

ȱ

ȼ

ɇ

ȱ

ɑ

ɇ

Ɉ

Ɇ

ɍ

Ɋ

ȿ

Ƚ

ȱ

Ɉ

ɇ

Ⱥ

ɏ

ɍ

Ʉ

Ɋ

Ⱥ

Ȳ

ɇ

ɂ

Ⱦɍ «ɇɚɰɿɨɧɚɥɶɧɢɣ ɿɧɫɬɢɬɭɬ ɮɬɢɡɿɚɬɪɿʀ ɿ ɩɭɥɶɦɨɧɨɥɨɝɿʀ

ɿɦ.Ɏ.Ƚ.əɧɨɜɫɶɤɨɝɨ ɇȺɆɇ ɍɤɪɚʀɧɢ»

ɜɭɥ.Ɇ.Ⱥɦɨɫɨɜɚ, 10, Ʉɢʀɜ, 03680, ɍɤɪɚʀɧɚ

SI “National institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine”

M. Amosova str., 10, Kyiv, 03680, Ukraine e-mail: gumenuk@ifp.kiev.ua

Ʉɥɸɱɨɜɿ ɫɥɨɜɚ:ɫɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ,ɡɚɯɜɨɪɸɜɚɧɿɫɬɶ ɿ ɩɨɲɢɪɟɧɿɫɬɶ ɜ ɍɤɪɚʀɧɿ

Key words: epidemiology of sarcoidosis, incidence and prevalence in Ukraine

Ɋɟɮɟɪɚɬ. Ɂɚɛɨɥɟɜɚɟɦɨɫɬɶ ɫɚɪɤɨɢɞɨɡɨɦ ɨɪɝɚɧɨɜ ɞɵɯɚɧɢɹ ɜ ɸɠɧɨɦ ɢ ɫɟɜɟɪɧɨɦ ɪɟɝɢɨɧɚɯ ɍɤɪɚɢɧɵ.

Ƚɭɦɟɧɸɤ Ƚ.Ʌ.ɉɪɨɜɟɞɟɧɨ ɫɪɚɜɧɢɬɟɥɶɧɨɟ ɢɡɭɱɟɧɢɟ ɡɚɛɨɥɟɜɚɟɦɨɫɬɢ ɢ ɪɚɫɩɪɨɫɬɪɚɧɟɧɧɨɫɬɢ ɫɚɪɤɨɢɞɨɡɚ ɨɪɝɚɧɨɜ

ɞɵɯɚɧɢɹ ɜ ɸɠɧɨɦ (ȺɊ Ʉɪɵɦ)ɢ ɫɟɜɟɪɧɨɦ (ɀɢɬɨɦɢɪɫɤɚɹ ɨɛɥɚɫɬɶ)ɪɟɝɢɨɧɚɯ ɍɤɪɚɢɧɵ ɩɨ ɞɚɧɧɵɦ ɨɛɪɚɳɚɟɦɨɫɬɢ

ɢ ɪɟɡɭɥɶɬɚɬɚɦ ɩɪɨɮɢɥɚɤɬɢɱɟɫɤɨɝɨ ɪɟɧɬɝɟɧɨɥɨɝɢɱɟɫɤɨɝɨ ɨɛɫɥɟɞɨɜɚɧɢɹ ɜ 2011 ɝɨɞɭ.ȼ ȺɊ Ʉɪɵɦ ɩɨɤɚɡɚɬɟɥɶ ɡɚ

-ɛɨɥɟɜɚɟɦɨɫɬɢ ɫɨɫɬɚɜɢɥ 1,08 ɧɚ 100 000 ɜɡɪɨɫɥɨɝɨ ɧɚɫɟɥɟɧɢɹ, ɩɨɤɚɡɚɬɟɥɶ ɪɚɫɩɪɨɫɬɪɚɧɟɧɧɨɫɬɢ – 4,59 ɧɚ 100 000. ȼ ɀɢɬɨɦɢɪɫɤɨɣ ɨɛɥɚɫɬɢ ɩɨɤɚɡɚɬɟɥɶ ɡɚɛɨɥɟɜɚɟɦɨɫɬɢ (2,62 ɧɚ 100 000) ɩɪɟɜɵɲɚɥ ɚɧɚɥɨɝɢɱɧɵɣ ɜ ȺɊ

Ʉɪɵɦ ɜ 2,4 ɪɚɡɚ.Ɋɚɫɩɪɨɫɬɪɚɧɟɧɧɨɫɬɶ (7,86 ɧɚ 100 000) ɛɵɥɚ ɜɵɲɟ,ɱɟɦ ɜ ȺɊ Ʉɪɵɦ,ɜ 1,5 ɪɚɡɚ.ȼ ɫɜɹɡɢ ɫ ɬɟɦ,

ɱɬɨ ɤɥɢɦɚɬɢɱɟɫɤɢɣ ɮɚɤɬɨɪ ɹɜɥɹɟɬɫɹ ɨɞɧɢɦ ɢɡ ɨɩɪɟɞɟɥɹɸɳɢɯ ɜ ɷɩɢɞɟɦɢɨɥɨɝɢɢ ɫɚɪɤɨɢɞɨɡɚ, ɩɨɤɚɡɚɬɟɥɢ ɡɚ

-ɛɨɥɟɜɚɟɦɨɫɬɢ ɢ ɪɚɫɩɪɨɫɬɪɚɧɟɧɧɨɫɬɢ ɜ ɸɠɧɨɦ ɢ ɫɟɜɟɪɧɨɦ ɪɟɝɢɨɧɚɯ, ɫ ɧɚɢɛɨɥɶɲɟɣ ɜɟɪɨɹɬɧɨɫɬɶɸ, ɦɨɠɧɨ

ɫɱɢɬɚɬɶ ɤɪɚɣɧɢɦɢ ɞɥɹ ɨɛɥɚɫɬɟɣ ɍɤɪɚɢɧɵ. ɗɬɨ ɞɚɟɬ ɨɫɧɨɜɚɧɢɟ ɡɚɤɥɸɱɢɬɶ, ɱɬɨ ɜ ɰɟɥɨɦ ɩɨ ɍɤɪɚɢɧɟ ɡɚ

-ɛɨɥɟɜɚɟɦɨɫɬɶ ɫɚɪɤɨɢɞɨɡɨɦ ɨɪɝɚɧɨɜ ɞɵɯɚɧɢɹ ɫɨɫɬɚɜɥɹɟɬ ɨɬ 1,1 ɞɨ 2,6 ɧɚ 100 000 ɜɡɪɨɫɥɨɝɨ ɧɚɫɟɥɟɧɢɹ,ɚ ɪɚɫ

-ɩɪɨɫɬɪɚɧɟɧɧɨɫɬɶ – ɨɬ 4,6 ɞɨ 7,9 ɧɚ 100 000, ɱɬɨ ɫɨɨɬɜɟɬɫɬɜɭɟɬ ɭɪɨɜɧɸ ɸɠɧɨɟɜɪɨɩɟɣɫɤɢɯ ɫɬɪɚɧ.

Abstract. Incidence of respiratory tract sarcoidosis in southern and northern regions of Ukraine. Gumenyuk G.L. We conducted a comparative survey of incidence and prevalence of pulmonary sarcoidosis in Southern (Crimean AR) and Northern (Zhytomyr region) regions of Ukraine by means of analysis of self-referred cases and cases, revealed at prophylactic radiological examination in 2011. The incidence of sarcoidosis in Crimea was 1.08 per 100 000 adult inhabitants; the prevalence was 4,59 per 100 000. In Zhytomyr region the incidence value (2,62 per 100 000) exceeded an equivalent value in Crimea by 2,4 times. The prevalence (7,86 per 100 000) was also higher than in Crimea by 1,7 times. Taking into account a significant impact of climate factor on sarcoidosis epidemiology, the incidence and prevalence of disease in Northern and Southern regions should be considered polar as for the regions of Ukraine. This makes it possoble to conclude that mean incidence of sarcoidosis in Ukraine ranges from 1,1 to 2,6 per 100 000 adult population, whereas the prevalence – from 4,6 to 7,9 per 100 000, which is equivalent to the level of Southern European countries.

ɋɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɽ ɧɚɣɱɚɫɬɿɲɨɸ ɧɨ

-ɡɨɥɨɝɿɱɧɨɸ ɮɨɪɦɨɸ ɜ ɫɬɪɭɤɬɭɪɿ ɿɧɬɟɪɫɬɢɰɿɚɥɶ

-ɧɢɯ ɡɚɯɜɨɪɸɜɚɧɶ ɥɟɝɟɧɶ (ȱɁɅ). ɍ Ȼɟɥɶɝɿʀ ɫɚɪ

-ɤɨʀɞɨɡ ɫɬɚɧɨɜɢɬɶ 27% ɜɫɿɯ ɜɢɩɚɞɤɿɜ ȱɁɅ,ɭ Ƚɪɟɰɿʀ – 34,1% [5], ɭ Ɏɪɚɧɰɿʀ ɫɚɪɤɨʀɞɨɡ ɬɚ ɿɞɿɨɩɚɬɢɱɧɢɣ

ɥɟɝɟɧɟɜɢɣ ɮɿɛɪɨɡ ɪɚɡɨɦ – ɛɿɥɶɲɟ 50% [4]. Ɂ 70-ɯ

ɪɨɤɿɜ ɦɢɧɭɥɨɝɨ ɫɬɨɪɿɱɱɹ ɫɩɨɫɬɟɪɿɝɚɽɬɶɫɹ ɧɟɜɩɢɧ

-ɧɟ ɡɪɨɫɬɚɧɧɹ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɧɚ ɫɚɪɤɨʀɞɨɡ ɬɚ ɫɦɟɪɬɧɨɫɬɿ ɯɜɨɪɢɯ [3, 11, 13].

Ɂɚɯɜɨɪɸɜɚɧɿɫɬɶ ɧɚ ɫɚɪɤɨʀɞɨɡ ɭ ɪɿɡɧɢɯ ɤɪɚʀɧɚɯ ɫɜɿɬɭ ɜɚɪɿɸɽ ɜɿɞ 0,125 ɞɨ 24,0 ɧɨɜɢɯ ɜɢɩɚɞɤɿɜ ɧɚ 100 000 ɧɚɫɟɥɟɧɧɹ ɧɚ ɪɿɤ,ɩɨɲɢɪɟɧɿɫɬɶ – ɜɿɞ 1 ɞɨ 64ɧɚ 100 000 ɧɚɫɟɥɟɧɧɹ [2]. Ȼɟɡɫɭɦɧɿɜɧɢɣ ɜɩɥɢɜ

ɧɚ ɡɚɯɜɨɪɸɜɚɧɿɫɬɶ ɧɚ ɫɚɪɤɨʀɞɨɡ ɦɚɽ ɤɥɿɦɚɬɢɱɧɢɣ ɮɚɤɬɨɪ – ɭ ɤɪɚʀɧɚɯ Ⱥɮɪɢɤɢ, Ⱥɡɿʀ ɬɚ ɐɟɧɬɪɚɥɶɧɨʀ

Ⱥɦɟɪɢɤɢ ɩɨɤɚɡɧɢɤɢ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɧɚɣɧɢɠɱɿ, ɚ

ɜ ɤɪɚʀɧɚɯ ɡ ɩɨɦɿɪɧɢɦ ɬɚ ɯɨɥɨɞɧɢɦ ɤɥɿɦɚɬɨɦ –

ɧɚɣɜɢɳɿ. Ɂɚɯɜɨɪɸɜɚɧɿɫɬɶ, ɹɤɚ ɩɟɪɟɜɢɳɭɽ 10 ɜɢ

-ɩɚɞɤɿɜ ɧɚ 100 000 ɧɚɫɟɥɟɧɧɹ ɧɚ ɪɿɤ, ɫɩɨɫɬɟɪɿ

-ɝɚɽɬɶɫɹ ɜ ɩɿɜɧɿɱɧɨɽɜɪɨɩɟɣɫɶɤɢɯ ɤɪɚʀɧɚɯ – Ⱦɚɧɿʀ (10,1),Ɏɿɧɥɹɧɞɿʀ (11,4), ɇɨɪɜɟɝɿʀ (15,0) ɬɚ ɒɜɟɰɿʀ (24,0) [7, 9, 12].

ȼ ɍɤɪɚʀɧɿ ɞɨ ɬɟɩɟɪɿɲɧɶɨɝɨ ɱɚɫɭ ɧɟ ɩɪɨɜɨ

-ɞɢɥɢɫɹ ɟɩɿɞɟɦɿɨɥɨɝɿɱɧɿ ɞɨɫɥɿɞɠɟɧɧɹ ɫɬɨɫɨɜɧɨ ɫɚɪɤɨʀɞɨɡɭ.

Ɇɟɬɚ ɞɨɫɥɿɞɠɟɧɧɹ – ɩɪɨɜɟɫɬɢ ɩɨɪɿɜɧɹɥɶɧɟ

ɜɢɜɱɟɧɧɹ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɧɚ ɫɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɜ ɩɿɜɞɟɧɧɨɦɭ ɬɚ ɩɿɜɧɿɱɧɨɦɭ ɪɟɝɿɨɧɚɯ ɍɤɪɚʀɧɢ.

ɆȺɌȿɊȱȺɅɂ ɌȺ ɆȿɌɈȾɂ ȾɈɋɅȱȾɀȿɇɖ

ɉɪɨɜɟɞɟɧɟ ɩɨɪɿɜɧɹɥɶɧɟ ɜɢɜɱɟɧɧɹ ɡɚɯɜɨɪɸ

(2)

ɋɈɐȱȺɅɖɇȺ ɆȿȾɂɐɂɇȺ

ɆȿȾɂɑɇȱ ɉȿɊɋɉȿɄɌɂȼɂ

160

ɞɢɯɚɧɧɹ ɜ ȺɊ Ʉɪɢɦ ɬɚ ɀɢɬɨɦɢɪɫɶɤɿɣ ɨɛɥɚɫɬɿ ɡɚ ɞɚɧɢɦɢ ɡɜɟɪɬɚɧɶ ɬɚ ɪɟɡɭɥɶɬɚɬɚɦɢ ɩɪɨɮɿɥɚɤɬɢɱ

-ɧɨɝɨ ɪɟɧɬɝɟɧɨɥɨɝɿɱ-ɧɨɝɨ ɨɛɫɬɟɠɟɧɧɹ ɜ 2011 ɪɨɰɿ.

ȼɿɞɨɦɨɫɬɿ ɩɪɨ ɧɨɜɿ ɜɢɩɚɞɤɢ ɫɚɪɤɨʀɞɨɡɭ ɛɭɥɢ ɨɬɪɢɦɚɧɿ ɜɿɞ ɩɭɥɶɦɨɧɨɥɨɝɿɱɧɨʀ, ɬɟɪɚɩɟɜɬɢɱɧɨʀ,

ɮɬɢɡɿɚɬɪɢɱɧɨʀ ɫɥɭɠɛ ɥɿɤɭɜɚɥɶɧɨ-ɩɪɨɮɿɥɚɤɬɢɱɧɢɯ

ɡɚɤɥɚɞɿɜ ɪɚɣɨɧɧɨɝɨ, ɦɿɫɶɤɨɝɨ, ɨɛɥɚɫɧɨɝɨ ɬɚ ɞɟɪ

-ɠɚɜɧɨɝɨ ɪɿɜɧɿɜ. Ɉɫɤɿɥɶɤɢ ɜ ɍɤɪɚʀɧɿ ɩɪɨɬɹɝɨɦ

ɞɟɤɿɥɶɤɨɯ ɞɟɫɹɬɤɿɜ ɪɨɤɿɜ ɫɤɥɚɥɚɫɹ ɩɪɚɤɬɢɤɚ,ɡɝɿɞ

-ɧɨ ɡ ɹɤɨɸ ɜɩɟɪɲɟ ɜɢɹɜɥɟɧɿ ɯɜɨɪɿ ɧɚ ɫɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɧɚɩɪɚɜɥɹɸɬɶɫɹ ɞɥɹ ɭɬɨɱɧɟɧɧɹ ɞɿɚɝɧɨɡɭ ɬɚ ɥɿɤɭɜɚɧɧɹ ɞɨ ɇɚɰɿɨɧɚɥɶɧɨɝɨ ɿɧɫɬɢ

-ɬɭɬɭ ɮɬɢɡɿɚɬɪɿʀ ɬɚ ɩɭɥɶɦɨɧɨɥɨɝɿʀ ɿɦɟɧɿ Ɏ.Ƚ.

əɧɨɜɫɶɤɨɝɨ, ɨɬɪɢɦɚɧɿ ɞɚɧɿ ɛɭɥɢ ɞɨɩɨɜɧɟɧɿ ɦɚɬɟ

-ɪɿɚɥɚɦɢ ɚɧɚɥɿɡɭ ɦɟɞɢɱɧɨʀ ɞɨɤɭɦɟɧɬɚɰɿʀ ɤɨɧɫɭɥɶ

-ɬɚɬɢɜɧɨʀ ɩɨɥɿɤɥɿɧɿɤɢ ȱɧɫɬɢɬɭɬɭ. Ɋɨɛɨɬɚ ɩɪɨɜɨ

-ɞɢɥɚɫɹ ɩɿɞ ɤɟɪɿɜɧɢɰɬɜɨɦ ɩɪɨɮ. ȼ.Ʉ.Ƚɚɜɪɢɫɸɤɚ

ɡɚ ɭɱɚɫɬɸ ɤ. ɦ. ɧ. Ɉ.Ⱥ.Ɇɟɪɟɧɤɨɜɨʀ, Ɉ.ȼ.ɒɚɞ

-ɪɿɧɨʀ, ɤ. ɦ. ɧ. Ɉ.Ⱥ.Ȼɟɪɟɧɞɢ, ɩɪɨɮ. Ⱥ.ȱ. əɱɧɢɤɚ.

Ɋɨɛɨɬɚ ɜɢɤɨɧɚɧɚ ɡɚ ɤɨɲɬɢ ɞɟɪɠɚɜɧɨɝɨ ɛɸɞɠɟɬɭ.

ɊȿɁɍɅɖɌȺɌɂ ɌȺ Ȳɏ ɈȻȽɈȼɈɊȿɇɇə

ȼ ȺɊ Ʉɪɢɦ ɱɢɫɥɨ ɧɨɜɢɯ ɜɢɩɚɞɤɿɜ ɫɬɚɧɨɜɢɥɨ

21 (14 ɠɿɧɨɤ ɬɚ 7 ɱɨɥɨɜɿɤɿɜ, ɫɟɪɟɞɧɿɣ ɜɿɤ – 50,3

ɪɨɤɭ). ɉɨɤɚɡɧɢɤ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ – 1,08 ɧɚ

100 000 ɞɨɪɨɫɥɨɝɨ ɧɚɫɟɥɟɧɧɹ. ȱ ɫɬɚɞɿɹ ɡɚɯɜɨɪɸ

-ɜɚɧɧɹ ɞɿɚɝɧɨɫɬɨɜɚɧɚ ɜ 9 ɩɚɰɿɽɧɬɿɜ (42,5%), ȱȱ

ɫɬɚɞɿɹ – ɭ 10 (47,6%), ȱȱȱ ɫɬɚɞɿɹ – ɭ 2 (9,5%). Ɂɚ

-ɝɚɥɶɧɚ ɤɿɥɶɤɿɫɬɶ ɯɜɨɪɢɯ ɡ ɚɤɬɢɜɧɢɦ ɫɚɪɤɨʀɞɨɡɨɦ ɭ 2011 ɪɨɰɿ – 89 (53 ɠɿɧɤɢ ɬɚ 36 ɱɨɥɨɜɿɤɿɜ,ɫɟɪɟɞ

-ɧɿɣ ɜɿɤ – 50,6 ɪɨɤɭ). ɉɨɤɚɡɧɢɤ ɩɨɲɢɪɟɧɨɫɬɿ – 4,59 ɧɚ 100 000. ȱ ɫɬɚɞɿɹ ɫɚɪɤɨʀɞɨɡɭ ɫɩɨɫɬɟɪɿɝɚ

-ɥɚɫɶ ɭ 14 ɯɜɨɪɢɯ (15,7%), ȱȱ ɫɬɚɞɿɹ – ɭ 46 (51,6%),

ȱȱȱ ɫɬɚɞɿɹ – ɭ 17 (19%), ȱVɫɬɚɞɿɹ – 12 (13%).

ɋɟɪɟɞ ɱɨɥɨɜɿɤɿɜ ɧɚɣɛɿɥɶɲɚ ɤɿɥɶɤɿɫɬɶ ɯɜɨɪɢɯ ɛɭɥɚ ɭ ɜɿɰɿ ɜɿɞ 40 ɞɨ 49 ɪɨɤɿɜ,ɭ ɠɿɧɨɤ ɩɿɤ ɡɚɯɜɨ

-ɪɸɜɚɧɨɫɬɿ ɫɩɨɫɬɟɪɿɝɚɜɫɹ ɜ ɫɟɪɟɞɧɶɨɦɭ ɧɚ 10

ɪɨɤɿɜ ɩɿɡɧɿɲɟ.

ɍ ɀɢɬɨɦɢɪɫɶɤɿɣ ɨɛɥɚɫɬɿ ɫɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɜɩɟɪɲɟ ɜɢɹɜɥɟɧɢɣ ɭ 2011 ɪɨɰɿ ɜ 27 ɯɜɨ

-ɪɢɯ (17 ɠɿɧɨɤ ɬɚ 10 ɱɨɥɨɜɿɤɿɜ,ɫɟɪɟɞɧɿɣ ɜɿɤ – 36,4

ɪɨɤɭ). ɉɨɤɚɡɧɢɤ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ (2,62 ɧɚ

100 000) ɩɟɪɟɜɢɳɭɜɚɜ ɚɧɚɥɨɝɿɱɧɢɣ ɜ ȺɊ Ʉɪɢɦ ɜ

2,4 ɪɚɡɭ. Ɂɚɝɚɥɶɧɚ ɤɿɥɶɤɿɫɬɶ ɯɜɨɪɢɯ ɡ ɚɤɬɢɜɧɢɦ

ɫɚɪɤɨʀɞɨɡɨɦ ɫɬɚɧɨɜɢɥɚ 81 (43 ɠɿɧɤɢ ɿ 38 ɱɨ

-ɥɨɜɿɤɿɜ, ɫɟɪɟɞɧɿɣ ɜɿɤ – 40,2 ɪɨɤɭ). ɉɨɤɚɡɧɢɤ

ɩɨɲɢɪɟɧɨɫɬɿ (7,86 ɧɚ 100 000) ɛɭɜ ɜɢɳɢɦ ɡɚ ȺɊ

Ʉɪɢɦ ɜ 1,7 ɪɚɡɭ.

Ɂɧɚɱɧɿ ɜɿɞɦɿɧɧɨɫɬɿ ɪɿɜɧɿɜ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɬɚ ɩɨɲɢɪɟɧɨɫɬɿ ɫɚɪɤɨʀɞɨɡɭ ɜ ɩɿɜɧɿɱɧɢɯ ɬɚ ɩɿɜɞɟɧɧɢɯ ɪɟɝɿɨɧɚɯ ɨɞɧɿɽʀ ɤɪɚʀɧɢ ɜɿɞɡɧɚɱɟɧɿ ɜ ȱɪɥɚɧɞɿʀ ɬɚ Ⱦɚɧɿʀ – ɤɪɚʀɧɚɯ,ɳɨ ɡɧɚɱɧɨ ɩɨɫɬɭɩɚɸɬɶɫɹ ɍɤɪɚʀɧɿ

ɡɚ ɪɨɡɦɿɪɚɦɢ. Ɍɚɤ, ɧɚ ɩɿɜɧɿɱɧɨɦɭ ɡɚɯɨɞɿ ȱɪɥɚɧɞɿʀ

ɡɚɯɜɨɪɸɜɚɧɿɫɬɶ ɫɬɚɧɨɜɢɬɶ 44,9 ɧɚ 100 000 [10].

ɉɪɢɛɥɢɡɧɨ ɚɧɚɥɨɝɿɱɧɿ ɜɿɞɦɿɧɧɨɫɬɿ ɜɿɞɡɧɚɱɟɧɿ ɣ ɭ Ⱦɚɧɿʀ [9].

ɍ ɀɢɬɨɦɢɪɫɶɤɿɣ ɨɛɥɚɫɬɿ ɦɚɤɫɢɦɚɥɶɧɢɣ ɪɿɜɟɧɶ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɫɟɪɟɞ ɱɨɥɨɜɿɤɿɜ ɭ ɜɿɤɨɜɿɣ ɝɪɭɩɿ

30– 39 ɪɨɤɿɜ. ɍ ɠɿɧɨɤ ɜɿɞɡɧɚɱɚɥɨɫɹ ɞɜɚ ɜɿɤɨɜɢɯ

ɩɿɤɢ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ, ɹɤɿ ɨɩɢɫɚɧɿ ɜ ɡɚɤɨɪɞɨɧɧɿɣ

ɥɿɬɟɪɚɬɭɪɿ. ɉɟɪɲɢɣ ɫɩɨɫɬɟɪɿɝɚɜɫɹ ɜ 20–29 ɪɨɤɿɜ,

ɞɪɭɝɢɣ – ɭ ɜɿɰɿ ɜɿɞ 40 ɞɨ 49 ɪɨɤɿɜ, ɩɪɢ ɰɶɨɦɭ

ɞɪɭɝɢɣ ɩɿɤ ɛɭɜ ɜɢɪɚɠɟɧɿɲɢɦ ɡɚ ɩɟɪɲɢɣ.

ɍ ɡɜ’ɹɡɤɭ ɡ ɬɢɦ, ɳɨ ɤɥɿɦɚɬɢɱɧɢɣ ɮɚɤɬɨɪ ɽ

ɨɞɧɢɦ ɡ ɜɢɡɧɚɱɚɥɶɧɢɯ ɜ ɟɩɿɞɟɦɿɨɥɨɝɿʀ ɫɚɪɤɨʀɞɨɡɭ,

ɩɨɤɚɡɧɢɤɢ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɬɚ ɩɨɲɢɪɟɧɨɫɬɿ ɜ ɩɿɜɞɟɧɧɨɦɭ ɬɚ ɩɿɜɧɿɱɧɨɦɭ ɪɟɝɿɨɧɚɯ ɡ ɛɿɥɶɲɨɸ ɜɿɪɨɝɿɞɧɿɫɬɸ ɦɨɠɧɚ ɜɜɚɠɚɬɢ ɤɪɚɣɧɿɦɢ ɞɥɹ ɨɛɥɚɫɬɟɣ ɍɤɪɚʀɧɢ. ɐɟ ɞɚɽ ɧɚɦ ɩɿɞɫɬɚɜɭ ɡɪɨɛɢɬɢ

ɜɢɫɧɨɜɨɤ, ɳɨ ɜ ɰɿɥɨɦɭ ɩɨ ɍɤɪɚʀɧɿ ɡɚɯɜɨɪɸ

-ɜɚɧɿɫɬɶ ɧɚ ɫɚɪɤɨʀɞɨɡ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɫɬɚɧɨɜɢɬɶ ɜ ɫɟɪɟɞɧɶɨɦɭ ɜɿɞ 1,1 ɞɨ 2,6 ɧɚ 100 000 ɞɨɪɨɫɥɨɝɨ

ɧɚɫɟɥɟɧɧɹ, ɚ ɩɨɲɢɪɟɧɿɫɬɶ – ɜɿɞ 4,6 ɞɨ 7,9 ɧɚ 100 000, ɳɨ ɜɿɞɩɨɜɿɞɚɽ ɪɿɜɧɸ ɩɿɜɞɟɧɧɨɽɜɪɨɩɟɣɫɶ

-ɤɢɯ ɤɪɚʀɧ. ȼɪɚɯɨɜɭɸɱɢ, ɳɨ ɞɨɪɨɫɥɟ ɧɚɫɟɥɟɧɧɹ

ɤɪɚʀɧɢ ɫɬɚɧɨɜɢɬɶ ɩɪɢɛɥɢɡɧɨ 38 ɦɥɧ ɨɫɿɛ, ɦɨɠɧɚ

ɩɪɢɩɭɫɬɢɬɢ, ɳɨ ɳɨɪɿɱɧɨ ɜ ɍɤɪɚʀɧɿ ɜɢɹɜɥɹɽɬɶɫɹ

ɛɥɢɡɶɤɨ 700 ɧɨɜɢɯ ɜɢɩɚɞɤɿɜ ɫɚɪɤɨʀɞɨɡɭ, ɚ ɡɚ

-ɝɚɥɶɧɚ ɤɿɥɶɤɿɫɬɶ ɯɜɨɪɢɯ ɡ ɚɤɬɢɜɧɢɦ ɫɚɪɤɨʀɞɨɡɨɦ ɫɬɚɧɨɜɢɬɶ ɩɪɢɛɥɢɡɧɨ 2500 ɬɢɫ.

ɇɟɨɛɯɿɞɧɨ ɜɿɞɡɧɚɱɢɬɢ, ɳɨ ɨɫɬɚɧɧɹ ɰɢɮɪɚ ɜɿ

-ɞɨɛɪɚɠɚɽ ɩɨɲɢɪɟɧɿɫɬɶ ɬɿɥɶɤɢ ɡɚɪɟɽɫɬɪɨɜɚɧɢɯ ɜɢɩɚɞɤɿɜ ɫɚɪɤɨʀɞɨɡɭ.ɐɟ ɩɚɰɿɽɧɬɢ, ɹɤɿ ɡɜɟɪɧɭɥɢɫɹ

ɡɚ ɦɟɞɢɱɧɨɸ ɞɨɩɨɦɨɝɨɸ ɚɛɨ ɜɢɹɜɥɟɧɿ ɩɪɢ ɩɪɨɮɿɥɚɤɬɢɱɧɨɦɭ ɪɟɧɬɝɟɧɨɥɨɝɿɱɧɨɦɭ ɨɛɫɬɟɠɟɧ

-ɧɿ. ȼɢɩɚɞɤɢ ɛɟɡɫɢɦɩɬɨɦɧɨɝɨ ɩɟɪɟɛɿɝɭ ɯɜɨɪɨɛɢ ɡɿ

ɫɩɨɧɬɚɧɧɢɦ ɨɞɭɠɚɧɧɹɦ ɡɚɥɢɲɚɸɬɶɫɹ ɡɚ ɦɟɠɚɦɢ ɩɨɥɹ ɡɨɪɭ ɥɿɤɚɪɿɜ.

ɉȱȾɋɍɆɈɄ

Ɋɟɡɭɥɶɬɚɬɢ ɞɨɫɥɿɞɠɟɧɧɹ ɩɿɞɬɜɟɪɞɢɥɢ ɡɚɥɟɠ

-ɧɿɫɬɶ ɩɨɤɚɡɧɢɤɿɜ ɟɩɿɞɟɦɿɨɥɨɝɿʀ ɫɚɪɤɨʀɞɨɡɭ ɨɪɝɚɧɿɜ ɞɢɯɚɧɧɹ ɜɿɞ ɤɥɿɦɚɬɢɱɧɨɝɨ ɮɚɤɬɨɪɭ ɡɿ ɡɛɿɥɶ

-ɲɟɧɧɹɦ ɪɿɜɧɹ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ ɣ ɩɨɲɢɪɟɧɨɫɬɿ ɡ ɩɿɜɞɧɹ ɧɚ ɩɿɜɧɿɱ. Ɍɚɤ, ɜ ȺɊ Ʉɪɢɦ (ɩɿɜɞɟɧɧɢɣ

ɪɟɝɿɨɧ)ɡɚɯɜɨɪɸɜɚɧɿɫɬɶ ɫɬɚɧɨɜɢɥɚ 1,08 ɧɚ 100 000

ɞɨɪɨɫɥɨɝɨ ɧɚɫɟɥɟɧɧɹ, ɩɨɲɢɪɟɧɿɫɬɶ – 4,59 ɧɚ 100 000. ɍ ɀɢɬɨɦɢɪɫɶɤɿɣ ɨɛɥɚɫɬɿ (ɩɿɜɧɿɱɧɢɣ

ɪɟɝɿɨɧ) ɩɨɤɚɡɧɢɤ ɡɚɯɜɨɪɸɜɚɧɨɫɬɿ (2,62 ɧɚ 100 000) ɩɟɪɟɜɢɳɭɜɚɜ ɚɧɚɥɨɝɿɱɧɢɣ ɜ ȺɊ Ʉɪɢɦ ɭ 2,4ɪɚɡɭ,ɩɨɤɚɡɧɢɤ ɩɨɲɢɪɟɧɨɫɬɿ (7,86 ɧɚ 100 000) – 1,7 ɪɚɡɭ. ɍ ɩɟɪɫɩɟɤɬɢɜɿ ɩɨɞɚɥɶɲɢɯ ɞɨɫɥɿɞɠɟɧɶ

ɩɥɚɧɭɽɬɶɫɹ ɜɢɜɱɟɧɧɹ ɫɬɪɭɤɬɭɪɢ ɯɜɨɪɢɯ ɡɚ ɤɥɿ

-ɧɿɱɧɢɦɢ ɮɨɪɦɚɦɢ ɬɚ ɫɬɚɞɿɹɦɢ,ɨɰɿɧɤɚ ɪɟɡɭɥɶɬɚɬɿɜ

ɥɿɤɭɜɚɧɧɹ ɡɚ ɞɚɧɢɦɢ ɪɟɬɪɨɫɩɟɤɬɢɜɧɨɝɨ ɞɨɫɥɿɞ

(3)

161

14/

Ɍɨɦ

XI

ɏ

/ 2

ɋ

ɉ

ɂ

ɋ

Ɉ

Ʉ

Ʌ

ȱ

Ɍ

ȿ

Ɋ

Ⱥ

Ɍ

ɍ

Ɋ

ɂ

1. Ȼɨɪɨɞɢɧɚ Ƚ.Ʌ. ɋɚɪɤɨɢɞɨɡ ɨɪɝɚɧɨɜ ɞɵɯɚɧɢɹ ɜ

ɪɟɫɩɭɛɥɢɤɟ Ȼɟɥɚɪɭɫɶ / Ƚ.Ʌ.Ȼɨɪɨɞɢɧɚ // Ɍɭɛɟɪɤɭɥɺɡ ɫɟ -ɝɨɞɧɹ: ɦɚɬɟɪɢɚɥɵ VII ɪɨɫ. ɫɴɟɡɞɚ ɮɬɢɡɢɚɬɪɨɜ. – Ɇ.: ɂɡɞ-ɜɨ ȻɂɇɈɆ, 2003. – ɋ. 340.

2. ȼɢɡɟɥɶ Ⱥ.Ⱥ.ɋɚɪɤɨɢɞɨɡ / Ⱥ.Ⱥ.ȼɢɡɟɥɶ // ɉɭɥɶ -ɦɨɧɨɥɨɝɢɹ:ɇɚɰɢɨɧɚɥɶɧɨɟ ɪɭɤɨɜɨɞɫɬɜɨ / ɩɨɞ ɪɟɞ.Ⱥ.Ƚ. ɑɭɱɚɥɢɧɚ. – Ɇ.:ȽɗɈɌȺɊ-Media, 2009. – ɋ. 681–695.

3. Duncan M.E. Mortality trends for tuberculosis and sarcoidosis in England / M.E. Duncan, M.J. Goldacre // Int. J. Tuberc. Lung Dis. – 2012. – Vol. 16, N 1. – P. 38–42.

4. Epidemiology of interstitial lung diseases / D. Va-leyre, O. Freynet, G. Dion [et al.] // Presse Med. – 2010. – Vol. 39, N 1. – P. 53–59.

5. Epidemiology of interstitial lung disease in Greece / A. Karakatsani, D. Papakosta, A. Rapti [et al.] // Respir. Med. – 2009. – Vol. 103, N 8. – P. 1122–1129.

6. Gillman A. Sarcoidosis in Australia / A. Gillman, C. Streinfort // Inter. Med. – 2007. – Vol. 37, N 6. – P. 356–359.

7. Milman N. Pulmonary sarcoidosis in the Nordic countries 1950–1082. Epidemiology and clinical picture / N. Milman, O. Selroos // Sarcoidosis. – 1990. – Vol. 7, N 1. – P. 50–57.

8. Roelandt M. Epidemiology of interstitial lung diseases (ILD) in flanders: registration by pneumologists

in 1992–1994. Working group on ILD, VRGT. Vere-niging voor Respiratore Gezondheidszorg en Tubercu-losebestrijding / M. Roelandt, M. Demedts, W. Callebaut // Acta Clin. Belg. – 1995. – Vol. 50, N 5. – P. 260–268.

9. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients / K.E. Byg, N. Milman, S. Hansen [et al.] // Sarcoidosis Vasc. Diffuse Lung Dis. 2003. Vol. 20, N 1. P. 4652.

10. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996–2005 / T.T. Nichol-son, B.J. Plant, M.T. Henry [et al.] // Sarcoidosis Vasc. Diffuse Lung Dis. 2010. Vol. 27, N 2. P. 111120.

11. Sarcoidosis-related mortality in the United States from 1988 to 2007 / J.J. Swigris, A.L. Olson, T.J. Huie [et al.] // Am. J. Resp. Crit. Care Med. – 2011. – Vol. 183, N 11. – P. 1524–1530.

12. The frequency of sarcoidosis in Finland and Hok-kaido, Japan. A comparative epidemiological study / A. Pietinalho, Y. Hiraga, Y. Hosoda [et al.] // Sarcoidosis. – 1995. – Vol.12, N 1. – P. 61–67.

13. Unexpectedly high prevalence of sarcoidosis in a representative U. S. Metropolian population / B.S. Erdal, B.D. Clymer, V.O. Yildiz [et al.] // Resp. Med. – 2012. – Vol. 106, N 6. – P. 893–899.

R

E

F

E

R

E

N

ɋ

E

S

1. Borodina GL. [Tuberculosis today: Proceedings of the VII congress of the Russian phthisiologists. Respiratory sarcoidosis in Belarus]. Moscow: Izdatelstvo BINOM. 2003;340. Russian.

2. Chuchalin AG, Vizel AA. [Pulmonology: Natio-nal guidelines. Sarcoidosis]. Moscow: GEOTAR-Media. 2009;681–695. Russian.

3. Duncan ME, Goldacre MJ. Mortality trends for tuberculosis and sarcoidosis in England. Int. J. Tuberc. Lung Dis. 2012;16(1):38–42.

4. Valeyre D, Freynet O, Dion G. Epidemiology of interstitial lung diseases. Presse Med. 2010;39(1):53–59.

5. Karakatsani A, Papakosta D, Rapti A. Epidemio-logy of interstitial lung disease in Greece. Respir. Med. 2009;103(8):1122–9.

6. Gillman A, Streinfort C. Sarcoidosis in Australia. Intern. Med. 2007;37(6):356–9.

7. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1082. Epidemiology and clini-cal picture. Sarcoidosis. 1990;7(1):50–57.

8. Roelandt M, Demedts M, Callebaut W. Epide-miology of interstitial lung diseases (ILD) in flanders: registration by pneumologists in 1992–1994. Working

group on ILD, VRGT. Vereniging voor Respiratore Gezo-ndheidszorg en Tuberculosebestrijding. Acta Clin. Belg. 1995;50(5):260–8.

9. Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc. Diffuse Lung Dis. 2003;20(1):4652.

10. Nicholson TT, Plant BJ, Henry MT. Sarcoidosis in Ireland: regional differences in prevalence and morta-lity from 1996–2005. Sarcoidosis Vasc. Diffuse Lung Dis. 2010;27(2):11120.

11. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am. J. Respir. Crit. Care Med. 2011;183(11):1524–30.

12. Pietinalho A, Hiraga Y, Hosoda Y, et al. The fre-quency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61–67.

13. Erdal BS, Clymer BD, Yildiz VO. Unexpectedly high prevalence of sarcoidosis in a representative U.S. Met-ropolian population. Respir. Med. 2012;106(6):893–9.